TSTX
Dead / Abandoned — Abandoned — no statement of use filed (as of 07 Jul 2025)
What this means for you
This application is over — abandoned 07 Jul 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98426361
- Mark type
- Stylized text
- Filed
- 28 Feb 2024
- Published for opposition
- 22 Oct 2024
- Abandoned
- 07 Jul 2025
- Attorney of record
- Sheila R. Gibson
Goods and services
- Class 005 — Pharmaceuticals: anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; pharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical compositions for the treatment of cancer; pharmaceutical drugs for the treatment of cancer; pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparations and substances for the treatment of treatment-resistant cancers biological preparations for the treatment of cancer; biological preparations for medical purposes for the treatment of cancer; medical preparations for the treatment of cancer; medicinal preparations and substances for the treatment of cancer; medicines for human purposes for the treatment of cancer; injectable pharmaceuticals for the treatment of cancer; compounds for treating resistant cancers; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for use in chemotherapy; anti-tumor preparations; anti-tumor drugs; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; preparations for treating malignant tumors; medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for treating gastrointestinal disorders
- Class 042 — Scientific and technological services: scientific research in the field of oncology; scientific research in the field of immuo-dysregulated diseases; development of pharmaceutical preparations and medicines for the treatment of cancer; development of pharmaceutical preparations and medicines for the treatment of immuno-dysregulated diseases; clinical research in the field of oncology; clinical research in the field of immuo-dysregulated diseases; research and development services in the field of anti-cancer preparations; research and development services in the field of preparations for treating immuno-dysregulated diseases; design, engineering, research, development and testing services in the field of oncology; design, engineering, research, development and testing services in the field of immuno-dysregulated diseases; providing information regarding medical research relating to oncology; providing information regarding medical research relating to immuno-dysregulated diseases
Owner
- Immix Biopharma, Inc., Los Angeles, CA, US
- Immix Biopharma, Inc., Los Angeles, CA, US
Prosecution history
- 07 Jul 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 07 Jul 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 03 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 22 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 22 Oct 2024 — PUBLISHED FOR OPPOSITION
- 02 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 Sept 2024 — ASSIGNED TO EXAMINER
- 10 Jul 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 29 Feb 2024 — NEW APPLICATION ENTERED